Managing acute exacerbations of schizophrenia: focus on quetiapine

References

• American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. www.psych.org [accessed 24 April 2003]
   Google Scholar
• Allen MH, Currier GW, Hughes DH, et al. The expert consensus guideline series: treatment of behavioral emergencies. Postgrad Med 2001:1–88 [Special Report]
   Google Scholar
• Gerlach J. Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Ann Clin Psychiatry 2002;14:47–57
   PubMedGoogle Scholar
• Arvanitis LA, Miller BG, the Seroquel Trial 13 study group. Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42: 233–46
   Google Scholar
• Copolov DL, Link CGG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophrenia. Psychol Med 2000;30: 95–105
   Google Scholar
• Emsley RA, Raniwalla J, Bailey PJ, et al. A comparison of the effects of quetiapine (‘Seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Int Clin Psychopharmacol 2000;15:121–31
   PubMed Web of Science ®Google Scholar
• Peuskens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96:265–73
   PubMed Web of Science ®Google Scholar
• Borison RL, Arvanitis LA, Miller BG, the US Seroquel Study Group. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996;16: 158–69
   Google Scholar
• Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997;54:549–57
   Google Scholar
• Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 2001;26:137–49
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Mullen JA, Sweitzer DE. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry 2002;63:1156–63
   Google Scholar
• Arvanitis LA, Rak IW. The long-term efficacy and safety of ‘Seroquel’ (quetiapine). Schizophr Res 1997;24:196–7
   Web of Science ®Google Scholar
• Buckley PF. Maintenance treatment for schizophrenia with quetiapine [in preparation]
   Google Scholar
• Kasper S. NR239: maintenance of long-term efficacy and safety of quetiapine in the treatment of schizophrenia. American Psychiatric Association 155th Annual Meeting, New Orleans, Louisiana, USA, 5–10 May 2002
   Google Scholar
• Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121–8
   PubMed Web of Science ®Google Scholar
• Allen MH, Carpenter D, Sheets JL, et al. What do consumers say they want and need during a psychiatric emergency? J Psychiatr Prac 2003;9:39–58
   PubMedGoogle Scholar
• McGlashan TH, Johannessen JO. Early detection and intervention with schizophrenia: rationale and research. Schizophr Bull 1996;22:201–22
   PubMed Web of Science ®Google Scholar
• Chengappa KNR, Goldstein JM, Greenwood M, et al. A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin Ther 2003;25:530–41
   PubMed Web of Science ®Google Scholar
• Arango C, Bernardo M. The effect of quetiapine on aggression and hostility in patients with schizophrenia [in preparation]
   Google Scholar
• Ganesan S, Levy M, Bilsker D. Effectiveness of quetiapine treatment of aggressive psychosis in the emergency psychiatric setting: a naturalistic pilot study. American Psychiatric Association 156th Annual Meeting, California, San Francisco, USA, 17–22 May 2003
   Google Scholar
• AstraZeneca. Seroquel® (quetiapine fumarate) tablets US Prescribing Information. www.Seroquel.com 2003
   Google Scholar
• AstraZeneca. Seroquel™ Prescribing Information Core International Data Sheet. www.psychiatry-in-practice.com 2003
   Google Scholar
• King DJ, Link CGG, Kowalcyk B. A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia. Psychopharmacology 1998;137:139–46
   Google Scholar
• Chengappa KNR, Parepally H, Brar JS, et al. A random-assignment, double-blind, clinical trial of once- vs twice-daily administration of quetiapine fumarate in patients with schizophrenia or schizoaffective disorder: a pilot study. Can J Psychiatry 2003;48:187–94
   PubMed Web of Science ®Google Scholar
• Smith MA, McCoy R, Hamer J, Brecher M. Optimal titration for quetiapine: pilot trial. College of Psychiatric and Neurologic Pharmacists 5th Annual Meeting, Seattle, Washington, USA, 18–21 April 2002
   Google Scholar
• Bobes J, Garcia-Portilla MP, Saiz PA, et al. High degree of tolerability for monotherapy with high doses of quetiapine: a case report. J Clin Psychiatry 2002;63:1048–9
   PubMed Web of Science ®Google Scholar
• De Nayer A, Windhager E, Irmansyah, et al. Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics. Int J Psychiatry Clin Pract 2003;7:59–66
   PubMed Web of Science ®Google Scholar
• Keks N, Tonso M, Tabone K, et al. Experience with atypical antipsychotics in an acute inpatient unit. International Congress on Schizophrenia Research, Colorado Springs, Colorado, USA, 29 March–2 April 2003
   Google Scholar
• Nagy J. Effectiveness of quetiapine up to 1600 mg/day: short-term results with 14-month follow-up. 16th European College of Neuropsychopharmacology Congress, Prague, Czech Republic, 20–24 September 2003
   Google Scholar
• Hellewell JS, Haddad PM. Differing tolerability profiles among atypical antipsychotics. Am J Psychiatry 2001;158:501–2
   PubMed Web of Science ®Google Scholar
• Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686–96
   PubMed Web of Science ®Google Scholar
• Olanzapine Prescribing Information. Zyprexa® (olanzapine) tablets. 2003
   Google Scholar
• Owens DGC. Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry 1994;55(Suppl 5):29–35
   PubMed Web of Science ®Google Scholar
• Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 1999;20:491–505
   PubMed Web of Science ®Google Scholar
• Hellewell JSE, Kalali AH, Langham SJ, et al. Patient satisfaction and acceptability of long-term treatment with quetiapine. Int J Psychiatry Clin Pract 1999;3:105–13
   PubMedGoogle Scholar
• Bartkó G, Váradi H, Simon L, et al. Patient satisfaction after switching from conventional to new atypical antipsychotics in schizophrenia. Int J Psychiatry Clin Pract 2002;6:9–14
   PubMed Web of Science ®Google Scholar
• Chue P, Abouelnasr W, Escobedo S, et al. A Canadian multicentre patient satisfaction study with oral long-term quetiapine treatment. Canadian Psychiatric Association, Banff, Alberta, Canada, 31 October–3 November 2002
   Google Scholar
• Simons WR, Bassi R, White R. Antipsychotic compliance evaluation: a population-based managed care study of persistence with initially prescribed antipsychotic medication. International Society for Pharmacoeconomics and Outcomes Research 4th Annual European Congress, Cannes, France, 11–13 November 2001
   Google Scholar
• Simons WR. Persistency and Compliance Evaluation (PACE): a US population-based analysis of persistency with initially prescribed antipsychotics. College of Psychiatric and Neurologic Pharmacists 6th Annual Meeting, Charleston, South Carolina, USA, 1–4 May 2003
   Google Scholar